Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
75
Recruiting, any sponsor type, condition "myelofibrosis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed276
75 trials
Showing 1 to 25, recently updated first.
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04811560 · 494 participants (planned) · Start May 19, 2021 · Primary completion Dec 29, 2028
Drug: Bleximenib · For: Acute Leukemia; Primary Myelofibrosis; Essential Thrombocythemia
Sites: Duarte, California; Orange, California; San Francisco, California · 102 sites in all
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07357727 · 460 participants (planned) · Start May 27, 2026 · Primary completion May 17, 2028
Drug: Pelabresib; Ruxolitinib and 1 more · For: Primary Myelofibrosis (PMF); Post-polycythemia Vera Myelofibrosis (PPV-MF); Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Sites: Denver, Colorado; New Haven, Connecticut; Fort Myers, Florida · 175 sites in all
Massachusetts General HospitalAcademic, hospital or other
NCT07104799 · 28 participants (planned) · Start Feb 23, 2026 · Primary completion Jan 2028
Drug: Momelotinib · For: Myelofibrosis; Hematopoietic Cell Transplantation (HCT)
Sites: Boston, Massachusetts
National Cancer Institute (NCI)NIH
NCT06661915 · 78 participants (planned) · Start Aug 14, 2025 · Primary completion Dec 31, 2027
Drug: Decitabine and Cedazuridine; Iadademstat · For: Accelerated Phase Myeloproliferative Neoplasm; Blast Phase Myeloproliferative Neoplasm; Essential Thrombocythemia and 5 more
Sites: Irvine, California; Orange, California; Palo Alto, California · 32 sites in all
- Study of INCA036978 in Participants With Myeloproliferative NeoplasmsPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT07441694 · 218 participants (planned) · Start May 11, 2026 · Primary completion May 24, 2030
Drug: INCA036978; Standard disease-directed therapy · For: Myeloproliferative Neoplasms
Sites: Birmingham, Alabama; Irvine, California; Los Angeles, California · 54 sites in all
- Study of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic DisordersRecruiting
Eilean TherapeuticsIndustry
NCT07529951 · 60 participants (planned) · Start Jun 1, 2026 · Primary completion Sep 30, 2028
Drug: ZE74-0282 · For: Polycythemia Vera (PV); Myelofibrosis (MF)
Sites: Nedlands, Australia; Tashkent, Uzbekistan
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
NCT06343805 · 256 participants (planned) · Start Oct 3, 2024 · Primary completion Jun 2027
Drug: LY5830966 · For: Primary Myelofibrosis
Sites: Palo Alto, California; Tampa, Florida; Kansas City, Kansas · 21 sites in all
- A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06351631 · 400 participants (planned) · Start May 23, 2024 · Primary completion Dec 4, 2034
Drug: Bomedemstat · For: Thrombocythemia, Essential; Primary Myelofibrosis; Myelofibrosis and 3 more
Sites: Ann Arbor, Michigan; Durham, North Carolina; Columbus, Ohio · 21 sites in all
- A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking RuxolitinibPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07623161 · 324 participants (planned) · Start Sep 10, 2026 · Primary completion Dec 7, 2029
Drug: Placebo; Elritercept · For: Myelofibrosis; Anemia
Sites: Gilbert, Arizona; Glendale, California; Whittier, California · 214 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06517875 · 68 participants (planned) · Start Feb 28, 2025 · Primary completion Mar 16, 2027
Drug: Momelotinib; Luspatercept · For: Primary Myelofibrosis; Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Sites: Ann Arbor, Michigan; New York, New York; Nashville, Tennessee · 33 sites in all
Prelude Therapeutics IncorporatedIndustry
NCT07469891 · 100 participants (planned) · Start Apr 29, 2026 · Primary completion Apr 2028
Drug: PRT12396 · For: Polycythemia Vera (PV); Myelofibrosis (MF); Myeloproliferative Neoplasms (MPNs) and 3 more
Sites: Los Angeles, California; Sacramento, California; Denver, Colorado · 22 sites in all
Ruijin HospitalAcademic, hospital or other
NCT07883382 · 10 participants (planned) · Start Oct 15, 2026 · Primary completion Oct 28, 2028
Drug: gecacitinib Hydrochloride Tablets · For: Myeloid Neoplasms With Myelofibrosis
Sites: Shanghai, China
John MascarenhasAcademic, hospital or other
NCT07447817 · 26 participants (planned) · Start Oct 23, 2026 · Primary completion May 24, 2030
Drug: Pacritinib; Selinexor · For: Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Sites: Westwood, Kansas; New York, New York; Winston-Salem, North Carolina
Damora TherapeuticsIndustry
NCT07849231 · 250 participants (planned) · Start Sep 2026 · Primary completion Jun 2030
Drug: DMR-001; Ruxolitinib · For: Myeloproliferative Neoplasms (MPNs)
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 36 sites in all
- AlloHCT With PegINFa for MyelofibrosisRecruiting
University of UtahAcademic, hospital or other
NCT05535764 · 18 participants (planned) · Start Aug 2, 2023 · Primary completion Jan 2027
Drug: Pegylated interferon alpha2a · For: Myelofibrosis
Sites: Salt Lake City, Utah
University of California, IrvineAcademic, hospital or other
NCT07281781 · 10 participants (planned) · Start Sep 16, 2025 · Primary completion Jun 2027
Drug: Nelfinavir · For: Myelofibrosis; Myelofibrosis; Anemia
Sites: Orange, California
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantPivotal-lookingRecruiting
City of Hope Medical CenterAcademic, hospital or other
NCT06059391 · 216 participants (planned) · Start Jul 9, 2024 · Primary completion Jan 1, 2027
Drug: Granulocyte Colony-Stimulating Factor; Hematopoietic Cell Transplantation Conditioning Regimen and 3 more · For: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia and 7 more
Sites: Duarte, California; Atlanta, Georgia; Boston, Massachusetts
City of Hope Medical CenterAcademic, hospital or other
NCT07020533 · 46 participants (planned) · Start Sep 9, 2026 · Primary completion Feb 14, 2030
Drug: Letermovir; Multi-peptide CMV-Modified Vaccinia Ankara Vaccine and 1 more · For: Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia and 9 more
Sites: Duarte, California; Atlanta, Georgia; Boston, Massachusetts
- Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaPivotal-lookingRecruiting
Disc Medicine, IncIndustry
NCT05320198 · 150 participants (planned) · Start Jun 6, 2022 · Primary completion May 2027
Drug: DISC-0974 · For: Myelofibrosis; Anemia; Anemia; Myelofibrosis and 4 more
Sites: Gilbert, Arizona; Duarte, California; Irvine, California · 35 sites in all
Washington University School of MedicineAcademic, hospital or other
NCT07379125 · 30 participants (planned) · Start May 20, 2026 · Primary completion Dec 31, 2028
Drug: PMD-026 · For: Myeloid Malignancy
Sites: St Louis, Missouri
Cellenkos, Inc.Industry
NCT05423691 · 24 participants (planned) · Start Dec 27, 2022 · Primary completion Apr 30, 2027
Drug: CK0804 · For: Myelofibrosis
Sites: Sacramento, California; New York, New York; The Bronx, New York · 4 sites in all
CERo Therapeutics Holdings, Inc.Industry
NCT06834282 · 18 participants (planned) · Start Apr 7, 2025 · Primary completion Dec 31, 2026
Drug: CER-1236; Cyclophosphamide and 2 more · For: AML; Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
Sites: Sacramento, California; Denver, Colorado; Nashville, Tennessee · 5 sites in all
- Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in MyelofibrosisRecruiting
University of UtahAcademic, hospital or other
NCT07521046 · 15 participants (planned) · Start Aug 21, 2026 · Primary completion Aug 2029
Drug: ropeginterferon alfa- 2b; Ruxolitinib · For: Myelofibrosis
Sites: Salt Lake City, Utah
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT07228624 · 50 participants (planned) · Start Feb 4, 2026 · Primary completion Sep 1, 2030
Drug: Ruxolitinib; Busulfan and 6 more · For: Myelodysplastic/Myeloproliferative Neoplasm; Primary Myelofibrosis; Secondary Myelofibrosis
Sites: Seattle, Washington
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07128381 · 66 participants (planned) · Start Jan 2, 2026 · Primary completion Jul 31, 2031
Drug: Axatilimab (SNDX-6352); Ruxolitinib · For: Myelofibrosis (MF); Chronic Myelomonocytic Leukemia (CMML)
Sites: Houston, Texas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.